Intellectual Property Office Home University of Cincinnati
News
Technologies
Issued US Patents
UC Technology Startups
Forms
Our Mission
IP Overview
Patents
Copyright
Licensing
Conflicts
Policies and Law
Annual Reports
Staff and Location
Contact Us
Links
UC Directory
IPO Home

Case Number 107054 - Novel End-Point Assay for Autophagy

Description:  Dr. Patrick Dennis at the University of Cincinnati developed a novel end-point assay for autophagy based on the observation that the BHMT (betaine homocysteine methyl transferase) enzyme is degraded via autophagy with the generation of a discrete proteolytic fragment in the lysosomal compartment (1). Dr. Dennis engineered a novel Glutathione-S-Transferase (GST)-BHMT reporter with targeted mutations that result in degradation of the fusion protein via the autophagocytic pathway. Autophagocytic degradation of the reporter leads to the generation of discrete proteolytic fragments in the lysosomal compartment, similar to native BHMT. The advantages of this autophagy assay over existing assays are 1) end-point assay rather than mid-point assay, 2) increased sensitivity and 3) less subjective and more quantifiable.




For more information please contact Ellen Monson at 513-558-5274 or geoffrey.pinski@uc.edu



Back to Technologies
 
Printer Friendly Version of Novel End-Point Assay for Autophagy - 107054









Copyright Information © Copyright 2004-2012 university of Cincinnati, Ohio. All rights reserved.